Medtronic diabetes receives fda warning letter

Dublin, dec. 15, 2021 /prnewswire/ -- medtronic plc (nyse:mdt) today announced it received a warning letter from the u.s. food and drug administration (fda) on december 9 for the company's northridge, california, facility, the headquarters for its diabetes business. the warning letter was issued following an inspection that concluded in july 2021 related to recalls of the minimed™ 600 series insulin infusion pump, and a remote controller device for minimed™ 508 and paradigm™ pumps.
MDT Ratings Summary
MDT Quant Ranking